A Study of Bortezomib plus (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma

Full Title

Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with(R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin’s Lymphoma (AMC Protocol #053) Back to top

Purpose

The purpose of this study is to find the highest dose of a drug called bortezomib (Velcade) that can be given safely with a chemotherapy regimen called (R)ICE in patients with HIV-associated non-Hodgkin’s lymphoma that has returned or persisted despite treatment and contains the Epstein-Barr virus (EBV) and/or human herpes virus 8 (HHV-8).

Bortezomib is used to treat a cancer called multiple myeloma and certain types of lymphoma. (R)ICE includes the drugs ifosfamide, carboplatin, and etoposide, which may or may not be given with rituximab. The effect of bortezomib for reducing the amount of HIV in the blood will also be studied.

Back to top

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have HIV-associated non-Hodgkin’s lymphoma that has returned or persisted despite treatment and contains EBV and/or HHV-8.
  • At least 3 weeks must have passed since completion of prior chemotherapy and 2 weeks since completion of any radiation therapy and entry into the study, and patients must have recovered from any side effects.
  • Patients must not be confined to a bed or chair for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. Ariela Noy at 212-639-7423.

Back to top

Protocol

09-063

Phase

Pilot

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

Locations